ArticleContemporary clinical trials communications2024
SECRETS: Subject-efficient clinical randomized controlled trials using synthetic intervention.
Article in Contemporary clinical trials communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Background: The parallel-group randomized controlled trial (RCT) is commonly used in Phase-3 clinical trials to establish treatment effectiveness but requires hundreds-to-thousands of subjects, making it difficult to implement, which leads to high Phase-3 trial failure rates. One approach to increasing power of a trial is to augment data collected from an RCT with external data from prospective studies or prior RCTs. However, this requires that external data be comparable to data from the study of interest, a condition that does not hold for new interventions or populations being studied. Another approach is to lower sample size requirements by using the cross-over design, which measures individual treatment effects (ITEs) to remove inter-subject variability; however, this design is only suitable for chronic conditions and interventions with effects that wash out rapidly. Method: We propose a novel and practical framework called SECRETS (Subject-Efficient Clinical Randomized Controlled Trials using Synthetic Intervention) to increase power of any parallel-group RCT by simulating the cross-over design using only data collected from the study. SECRETS first estimates ITEs across all subjects recruited to the RCT by using a state-of-the-art counterfactual estimation algorithm called synthetic intervention (SI). Since SI induces dependencies among the ITEs, we introduce a novel hypothesis testing strategy to test for treatment effectiveness. Results: We show that SECRETS can increase the power of an RCT while maintaining comparable significance levels; in particular, on three real-world clinical RCTs (Phase-3 trials), SECRETS increases power over the baseline method by Conclusion: SECRETS increases subject efficiency of an RCT by simulating the cross-over design using only data collected from the RCT; therefore, it is a feasible solution for increasing the trial's power, especially under settings where satisfying sample size requirements is difficult.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.